Sep 2026· Cancer Cell· Vol 44, pp. 1746 - 1760.e4· 1 citation· 53 references
Medicine
TL;DR
The data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Abstract
SUMMARY We performed an integrated clinical and genomic analysis of over 7,000 consecutively sequenced colorectal cancer (CRC) samples to comprehensively characterize genetic drivers and metastatic tropisms of CRC. We find that genomic evolutionary changes, such as clonal mutations and oncogenic mutant allele imbalance, selectively enhance the impact of recurrent oncogenic alterations. We identify the relative timing of organ-specific metastasis, showing sequential metastatic progression in microsatellite stable CRC with brain and adrenal metastases as late events; metastatic sites that cluster together, such as lung, bone, and brain metastases; and genomic events that enhance or decrease risk for each metastatic site with WNT pathway activation as overall protective while RAS pathway activation increased risk for spread to all metastatic sites. Our data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Across 236 whole-genome sequencing osteosarcoma samples, five genomic hotspots of clustered structural variation collectively altered in 58% of tumors were uncovered, and localized transcriptional dysregulation at hotspot event loci was found, linking these structural alterations to a less differentiated cell state.
Shreya Raman, Thorsten Kaltenbacher, David Merrell et al.· bioRxiv· 0 citations
Functional enrichment analysis revealed that epithelial-mesenchymal transition plays a critical role in CRC tumorigenesis and metastasis, and established a novel three-gene prognostic signature that effectively predicts clinical outcomes in CRC patients.
Ya-Ru Zhu, Di-Ya Liu, Zhen Ren et al.· Molecular and Cellular Bioch...· 0 citations
Primary tumors show an immunosuppressive phenotype, suggesting potential benefits from combining CTLA4 or IDO1 inhibitors with PD-1 blockade, and Liver metastases exhibit distinct immune features, supporting the need for site-specific precision therapies.
Ying Lu, T. Han, Li-Hui Wang et al.· Frontiers in Oncology· 0 citations
Background Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and mortality worldwide, and metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited treatment options. Mutations in the KRAS, BRAF oncogenes are key molecular drivers of colorectal cancer development a...
G. Kulmambetova, P. Tarlykov, D. Auganova et al.· Frontiers in Medicine· 0 citations
TP53 and FOXA1 mutations, observed in primary and metastatic castration-resistant prostate cancer, were associated with aggressive disease phenotypes and potential therapeutic resistance, and these findings highlight TP53 and FOXA1 as promising biomarkers and potential therapeutic targets in prostate cancer.
Metastatic cancer remains largely incurable and is responsible for the majority of cancer-related deaths. Despite this, therapeutic strategies are still predominantly guided by insights from primary tumors, often overlooking the distinct biological features of clinical metastases. In this Review, we provide an overview...
Guang-Lin Niu, C. Hagerling· Oncogene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.